Go Pro
→ Ready to give options a try? Your first trade (Ticker included) -INSIDE (From Base Camp Trading) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
$228.65
$272.86
$197.81
▼
$495.55
$30.60B0.32.24 million shs1.53 million shs
argenex SE stock logo
ARGX
argenex
$851.29
$881.73
$645.16
▼
$953.58
$53.26B0.46290,181 shs278,699 shs
Natera, Inc. stock logo
NTRA
Natera
$309.93
$263.76
$156.71
▼
$326.03
$44.67B1.511.30 million shs1.27 million shs
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$803.48
$675.79
$541.00
▼
$821.11
$82.73B0.21836,772 shs425,594 shs
7 Stocks to Buy Before the Robotics Revolution Cover
7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries.

"Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
0.00%+4.31%-14.51%-20.13%-49.07%
argenex SE stock logo
ARGX
argenex
0.00%-1.59%-1.08%+9.67%+30.20%
Natera, Inc. stock logo
NTRA
Natera
0.00%-3.78%+14.20%+60.97%+90.12%
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
0.00%+2.44%+18.74%+27.60%+38.43%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
$228.65
$272.86
$197.81
▼
$495.55
$30.60B0.32.24 million shs1.53 million shs
argenex SE stock logo
ARGX
argenex
$851.29
$881.73
$645.16
▼
$953.58
$53.26B0.46290,181 shs278,699 shs
Natera, Inc. stock logo
NTRA
Natera
$309.93
$263.76
$156.71
▼
$326.03
$44.67B1.511.30 million shs1.27 million shs
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$803.48
$675.79
$541.00
▼
$821.11
$82.73B0.21836,772 shs425,594 shs
7 Stocks to Buy Before the Robotics Revolution Cover
7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries.

"Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
0.00%+4.31%-14.51%-20.13%-49.07%
argenex SE stock logo
ARGX
argenex
0.00%-1.59%-1.08%+9.67%+30.20%
Natera, Inc. stock logo
NTRA
Natera
0.00%-3.78%+14.20%+60.97%+90.12%
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
0.00%+2.44%+18.74%+27.60%+38.43%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
2.92
Moderate Buy$393.8672.25% Upside
argenex SE stock logo
ARGX
argenex
2.92
Moderate Buy$1,056.8924.15% Upside
Natera, Inc. stock logo
NTRA
Natera
2.82
Moderate Buy$319.383.05% Upside
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
2.62
Moderate Buy$801.70-0.22% Downside

Current Analyst Ratings Breakdown

Latest ALNY, REGN, ARGX, and NTRA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/17/2026
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
Leerink Partners logo
Leerink Partners
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetMarket Perform$641.00 ➝ $824.00
8/14/2026
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
Wells Fargo & Company logo
Wells Fargo & Company
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetEqual Weight$316.00 ➝ $256.00
8/13/2026
Natera, Inc. stock logo
NTRA
Natera
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$315.00 ➝ $365.00
8/12/2026
Natera, Inc. stock logo
NTRA
Natera
Stephens logo
Stephens
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$305.00 ➝ $350.00
8/12/2026
Natera, Inc. stock logo
NTRA
Natera
Guggenheim logo
Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$290.00 ➝ $360.00
8/12/2026
Natera, Inc. stock logo
NTRA
Natera
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong Sell ➝ Hold
8/12/2026
Natera, Inc. stock logo
NTRA
Natera
Piper Sandler logo
Piper Sandler
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$249.00 ➝ $363.50
8/10/2026
Natera, Inc. stock logo
NTRA
Natera
Morgan Stanley logo
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOverweight$355.00
8/7/2026
Natera, Inc. stock logo
NTRA
Natera
TD Cowen logo
TD Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$325.00 ➝ $340.00
8/7/2026
Natera, Inc. stock logo
NTRA
Natera
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$275.00 ➝ $350.00
8/7/2026
Natera, Inc. stock logo
NTRA
Natera
Robert W. Baird logo
Robert W. Baird
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$348.00
(Data available from 8/17/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
$4.80B6.37$2.80 per share81.77$5.97 per share38.30
argenex SE stock logo
ARGX
argenex
$4.25B12.54$21.34 per share39.90$118.34 per share7.19
Natera, Inc. stock logo
NTRA
Natera
$2.31B19.37N/AN/A$12.38 per share25.03
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$14.34B5.77$41.98 per share19.14$295.66 per share2.72
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
$313.75M$5.3842.5023.69N/A15.26%84.93%14.30%10/29/2026 (Estimated)
argenex SE stock logo
ARGX
argenex
$1.29B$26.0432.6923.421.0532.19%43.59%36.66%N/A
Natera, Inc. stock logo
NTRA
Natera
-$208.16M-$1.36N/A30,993.00N/A-7.11%-11.38%-7.87%11/5/2026 (Estimated)
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$4.50B$40.4619.8615.901.3727.86%13.47%10.34%10/28/2026 (Estimated)

Latest ALNY, REGN, ARGX, and NTRA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2026Q2 2026
Natera, Inc. stock logo
NTRA
Natera
-$0.4939-$0.47+$0.0239-$0.47$661.24 million$752.75 million
7/30/2026Q2 2026
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$10.16$14.29+$4.13$12.23$3.82 billion$4.29 billion
7/21/2026Q2 2026
argenex SE stock logo
ARGX
argenex
$5.86$7.32+$1.46$7.32$1.45 billion$1.54 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
N/AN/AN/AN/AN/A
argenex SE stock logo
ARGX
argenex
N/AN/AN/AN/AN/A
Natera, Inc. stock logo
NTRA
Natera
N/AN/AN/AN/AN/A
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$3.760.47%N/A9.29%N/A

Latest ALNY, REGN, ARGX, and NTRA Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
7/30/2026
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
quarterly$0.940.51%8/18/20268/18/20268/31/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
0.75
3.05
2.99
argenex SE stock logo
ARGX
argenex
N/A
5.12
4.89
Natera, Inc. stock logo
NTRA
Natera
N/A
3.00
2.85
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
0.06
3.34
2.78

Institutional Ownership

CompanyInstitutional Ownership
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
92.97%
argenex SE stock logo
ARGX
argenex
60.32%
Natera, Inc. stock logo
NTRA
Natera
99.90%
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
83.31%

Insider Ownership

CompanyInsider Ownership
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
0.86%
argenex SE stock logo
ARGX
argenex
2.43%
Natera, Inc. stock logo
NTRA
Natera
5.05%
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
6.97%
CompanyEmployeesShares OutstandingFree FloatOptionable
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
2,770133.81 million132.66 millionOptionable
argenex SE stock logo
ARGX
argenex
1,86362.56 million61.04 millionOptionable
Natera, Inc. stock logo
NTRA
Natera
6,140144.14 million136.87 millionOptionable
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
15,410102.96 million95.78 millionOptionable

Recent News About These Companies

Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Raised to $824.00 at Leerink Partners
 |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/regeneron-pharmaceuticals-nasdaqregn-price-target-raised-to-82400-at-leerink-partners-2026-08-17/
Plato Investment Management Ltd Makes New $2.47 Million Investment in Regeneron Pharmaceuticals, Inc. $REGN
 |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-plato-investment-management-ltd-makes-new-247-million-investment-in-regeneron-pharmaceuticals-inc-regn-2026-08-17/
Oppenheimer Asset Management Inc. Takes $1.50 Million Position in Regeneron Pharmaceuticals, Inc. $REGN
 |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-oppenheimer-asset-management-inc-takes-150-million-position-in-regeneron-pharmaceuticals-inc-regn-2026-08-17/
Focus Partners Advisor Solutions LLC Invests $1.35 Million in Regeneron Pharmaceuticals, Inc. $REGN
August 17 at 3:59 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-focus-partners-advisor-solutions-llc-invests-135-million-in-regeneron-pharmaceuticals-inc-regn-2026-08-17/
AMG National Trust Bank Makes New $1.22 Million Investment in Regeneron Pharmaceuticals, Inc. $REGN
August 17 at 3:12 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-amg-national-trust-bank-makes-new-122-million-investment-in-regeneron-pharmaceuticals-inc-regn-2026-08-17/
Bronstein, Gewirtz & Grossman LLC Urges Regeneron Pharmaceuticals, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
August 16 at 12:00 PM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/16/3345782/9788/en/bronstein-gewirtz-grossman-llc-urges-regeneron-pharmaceuticals-inc-investors-to-act-class-action-filed-alleging-investor-harm.html
USA Financial Formulas Acquires New Position in Regeneron Pharmaceuticals, Inc. $REGN
August 16 at 6:07 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-usa-financial-formulas-acquires-new-position-in-regeneron-pharmaceuticals-inc-regn-2026-08-16/
REGN INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Regeneron Investors of Securities Class Action Lawsuit Deadline on September 14, 2026
August 15 at 9:31 PM  |  newsfilecorp.comN
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Regeneron Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines – REGN
August 15 at 10:00 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/15/3345720/1087/en/investor-alert-pomerantz-law-firm-reminds-investors-with-losses-on-their-investment-in-regeneron-pharmaceuticals-inc-of-class-action-lawsuit-and-upcoming-deadlines-regn.html
7,506 Shares in Regeneron Pharmaceuticals, Inc. $REGN Acquired by Summit Global Investments
August 15 at 6:55 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-7506-shares-in-regeneron-pharmaceuticals-inc-regn-acquired-by-summit-global-investments-2026-08-15/
Regeneron Pharmaceuticals (NASDAQ:REGN) Upgraded to "Strong-Buy" at Wall Street Zen
August 15 at 1:54 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30961527
Wall Street Zen Upgrades Regeneron Pharmaceuticals (NASDAQ:REGN) to Strong-Buy
August 15 at 1:53 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/wall-street-zen-upgrades-regeneron-pharmaceuticals-nasdaqregn-to-strong-buy-2026-08-15/
Is Biohaven (BHVN)’s Latest Regeneron Pharmaceuticals (REGN) Deal a Major Catalyst for its Pipeline?
August 14 at 7:08 PM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/biohaven-bhvn-latest-regeneron-pharmaceuticals-222352923.html
GLP-1 Demand Is Soaring. 2 Stocks That Could Benefit From This (Hint: Not Eli Lilly or Novo Nordisk)
August 14 at 7:08 PM  |  fool.comhttps://www.fool.com/investing/2026/08/14/glp-1-demand-is-soaring-2-stocks-that-could-benefi/
Regeneron Pharmaceuticals, Inc. (REGN) Investors: September 14, 2026 Lead Plaintiff Deadline in Class Action Lawsuit - Hagens Berman
August 14 at 3:34 PM  |  prnewswire.comhttps://www.prnewswire.com/news-releases/regeneron-pharmaceuticals-inc-regn-investors-september-14-2026-lead-plaintiff-deadline-in-class-action-lawsuit--hagens-berman-302852043.html
BMS builds big in Texas; Regeneron backs would-be rival
August 14 at 2:07 PM  |  pharmavoice.comP
The Gross Law Firm Reminds Regeneron Pharmaceuticals, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of September 14, 2026 - REGN
August 14 at 10:33 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/14/3345457/0/en/the-gross-law-firm-reminds-regeneron-pharmaceuticals-inc-investors-of-the-pending-class-action-lawsuit-with-a-lead-plaintiff-deadline-of-september-14-2026-regn.html
Regeneron Pharmaceuticals, Inc. Notice of September 14, 2026 Application Deadline for Class Action Lawsuit - Contact Reed Kathrein at Hagens Berman Sobol Shapiro LLP Before Application Deadline
August 13, 2026  |  newsfilecorp.comN
REGN Shareholder Alert: Regeneron Pharmaceuticals, Inc. Securities Class Action Lawsuit - Investors Should Contact SueWallSt
August 13, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/regn-shareholder-alert-regeneron-pharmaceuticals-inc-securities-class-action-lawsuit---investors-should-contact-suewallst-302851166.html
Parabilis Medicines Reports Second Quarter 2026 Financial Results and Provides Business Updates
August 13, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/parabilis-medicines-reports-second-quarter-110000177.html
REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm
August 13, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/13/3344680/0/en/regn-investors-have-opportunity-to-lead-regeneron-pharmaceuticals-inc-securities-fraud-lawsuit-with-the-schall-law-firm.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

Alnylam Pharmaceuticals stock logo

Alnylam Pharmaceuticals NASDAQ:ALNY

$228.65 0.00 (0.00%)
Closing price 08/14/2026 04:00 PM Eastern
Extended Trading
$229.75 +1.10 (+0.48%)
As of 09:26 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

argenex stock logo

argenex NASDAQ:ARGX

$851.29 0.00 (0.00%)
Closing price 08/14/2026 04:00 PM Eastern
Extended Trading
$935.20 +83.91 (+9.86%)
As of 09:27 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. It has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

Natera stock logo

Natera NASDAQ:NTRA

$309.93 0.00 (0.00%)
Closing price 08/14/2026 04:00 PM Eastern
Extended Trading
$311.47 +1.54 (+0.50%)
As of 09:22 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was founded in 2003 and is headquartered in Austin, Texas.

Regeneron Pharmaceuticals stock logo

Regeneron Pharmaceuticals NASDAQ:REGN

$803.48 0.00 (0.00%)
Closing price 08/14/2026 04:00 PM Eastern
Extended Trading
$806.44 +2.96 (+0.37%)
As of 09:27 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas